Rheumatoid Arthritis Research Studies
The Division of Rheumatology strives to understand more about rheumatoid arthritis (RA) through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
| Study Name/IRB#/PI | Brief Description | Basic Eligibility Criteria | Contact |
StopRA:National 24-1080 Kevin Deane, MD/PhD Christopher Striebich, MD/PhD | StopRA:National is a study being conducted by The Autoimmune Disease Prevention Center (ADPC) at the University of Colorado and designed to follow people who are at-risk of developing RA based on having a positive anti-CCP test, but without a diagnosis of RA. The goal of StopRA:National is to create opportunities for anti-CCP+ individuals without clinical RA to participate in research to help us learn more about RA development, and ultimately how to prevent RA. | Individuals who over the age of 18, with a positive CCP blood test without a diagnosis of RA | 303-724-0945 To learn more, visit our website: StopRA:National for Providers |
Interdisciplinary Joint Biology Program for Rheumatic and Orthopedic Diseases 20-1908 Larry Moreland, MD | The goal of the University of Colorado Interdisciplinary Joint Biology Program is to employ cutting edge science and technology to advance the research of inflammatory, degenerative and musculoskeletal joint diseases. | Individuals with RA, SpA, PsA, AS, OA or any other form of inflammatory arthritis with active disease in their elbow, wrist, hand joints, knee, ankle or shoulder and are willing to undergo a synovial biopsy at that site or individuals who are having an orthopedic surgery and are willing to donate their tissues that would normally be discarded | 303-724-7541
Or visit |
CPIRA-2 20-2619 Kevin Deane, MD | A study designed to learn more about pain in early Rheumatoid Arthritis. It’s a 1 year study with 3 visits (baseline, 3 months, 1 year). | Individuals with Rheumatoid Arthritis for less than 6 months may be eligible | 303-724-7510 |
ALTRA 19-1150Kevin Deane, MD | To learn about the immune system and microbiome in individuals at risk for developing RA | History of CCP+ blood test, or a close relative (parent, sibling, child) with RA or New diagnosis of RA | 303-724-8330 Or visit website: |
RA-SCREEN 22-1580 PI: M. Kristen Demoruelle, MD, PhD | An observational study designed to raise awareness about RA in the community and identify individuals who might be at risk for developing RA in the future. Visit consists of: bloodwork and online questionnaires and possible joint exam | At least 18 years old and one of the following:
| 303-724-0071 For more information visit: |
AMP-AIM 23-0022 Larry Moreland, MD | An observational study to better understand joint destruction in patients with autoimmune disorders like rheumatoid arthritis and develop new treatments | We are recruiting individuals who are newly diagnosed with rheumatoid arthritis and have a swollen knee or wrist | 303-724-7541
|
SELECT-SWITCH IRB# 23-1332 Elena Weinstein, MD | To evaluate the efficacy and safety of Upadacitinib vs. Adalimumab in subjects with RA who had inadequate response or intolerance to a single TNF inhibitor plus MTX To review the clinical trials.gov info click here | - Active RA despite ≥ 3 months treatment with 1 TNFi (but must be naive to HUMIRA) -Must be on stable MTX (oral or parenteral) and folic acid throughout the study. | 303-724-7518
303-724-7512 |
Sonoma Biotherapeutics 22-1945 Larry Moreland, MD | A clinical trial of chimeric antigen receptor (CAR) T cell therapy, which is a relatively new therapeutic approach that uses a patient's own immune cells to treat their rheumatoid arthritis | Individuals with moderate to severe rheumatoid arthritis that is not well managed by their current medication and who have a swollen knee or wrist. | 303-724-8784
|
SAPPHIRE Study of the Association between Cellular Processes in the Lung & Blood and Patient Health in Individuals with Rheumatoid Arthritis with and without Evidence of Interstitial Lung Disease 23-0089 Kristen Demoruelle, MD, PhD | An observational study designed to learn more about the causes of Interstitial Lung Disease (ILD) in RA. | At least 18 years old and one of the following: Diagnosis of RA +/- associated ILD | 303-724-7597 For more information visit: www.slayRA.com |
Control-RA (ITN) 22-1353 Larry Moreland, MD | A clinical trial to test whether a new study drug dazodalibep combined with Enbrel or Humira can be a more effective treatment for rheumatoid arthritis than taking any of these medications on their own. |
| 303-724-8784 |
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.